利用唾液腺分泌性癌症的器官样结构，经过TRK抑制剂治疗，进行精准肿瘤学研究。
Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors.
发表日期：2023 Feb
作者：
Gerben Lassche, Adriana C H van Engen-van Grunsven, Onno van Hooij, Tilly W Aalders, Jetty Am Weijers, Emiliano Cocco, Alexander Drilon, Alexander Hoischen, Kornelia Neveling, Jack A Schalken, Gerald W Verhaegh, Carla M L van Herpen
来源：
ORAL ONCOLOGY
摘要：
靶向特定分子肿瘤特征的抗癌药物在临床实践中的使用正迅速增加，但是选择受益的患者仍然是一个挑战。有人认为，器官样培养在体外测试药物反应是非常适合的。在这里，我们深入描述和表征了一例合成第6条电视台-神经营养因子受体激酶3基因融合阳性的唾液腺分泌癌，以及其对TRK靶向治疗（包括拉罗替尼）反应并随后获得耐药性的器官样培养。这个案例-培养-表征展示了精准肿瘤学方面取得的进展，但也揭示了使用器官样培养来预测治疗反应的重要局限性。 Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
The use of anticancer drugs targeting specific molecular tumor characteristics is rapidly increasing in clinical practice, but selecting patients to benefit from these remains a challenge. It has been suggested that organoid cultures would be ideally suited to test drug responses in vitro. Here we describe and characterize in depth a case of ETV6-NTRK3 gene fusion-positive secretory carcinoma of the salivary glands and corresponding organoid cultures that responded and subsequently acquired resistance to TRK targeting therapy with larotrectinib. This case-culture-characterization illustrates the advances made in precision oncology, but also exposes important caveats in using organoids to predict treatment response.Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.